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Background: Substantial bovine viral diarrhea virus (BVDV)-related production losses in North American alpaca herds
have been associated with BVDV type Ib infection.
Objectives: To classify and differentiate the long-term clinicopathological characteristics of BVDV type Ib infection of al-
paca crias, after natural virus exposure. We hypothesized that persistently infected (PI) alpacas specifically demonstrate growth
retardation, clinicopathological evidence of opportunistic infections, and early mortality.
Animals: Thirty-five crias naturally exposed to BVDV (18 acute, 3 chronic, 14 PIs), and 19 healthy cohort controls of 5
northeastern alpaca farms were prospectively evaluated over 2 years (September 2005–September 2008).
Methods: Observational cohort-control study.
Results: Chronically (viremia 43 weeks) and PI crias demonstrated significantly lower birth weights, decreased growth
rates, anemia, and monocytosis compared with control animals. Common clinical problems of PI alpacas included chronic
wasting, diarrhea, and respiratory disease.Median survival of PI alpacas that died was 177 days (interquartile range, 555) with a
case fatality rate of 50%within 6 months of life. Transplacental infection was confirmed in 82% (9/11) of pregnant females on 1
farm, resulting in the birth of 7 PI crias (7/10 deliveries; 1 animal was aborted). Mean gestation at the beginning and end of
BVDV exposure was 64 and 114 days, respectively.
Conclusions and Clinical Importance: Natural BVDV type 1b infection during early pregnancy resulted in a high incidence
of PI offspring. Although PI alpacas may have distinct clinical characteristics, verification of persistent viremia in the absence of
endogenous, neutralizing antibodies is essential to differentiate persistent from chronic infection.
Key words: Bovine viral diarrhea; Camelid; Persistent infection.
B
ovine viral diarrhea virus (BVDV) has been recog-
nized as a potential cause of serious illness, including
diarrhea, reproductive loss, wastage, and death in South
American camelids (SAC), posing a substantial threat to
herd health.1 BVDV is a member of the genus Pestivirus
in the family Flaviviridae that exists in 2 biotypic forms
(cytopathic and noncytopathic). Infection of both came-
lids2 and cattle in early gestation with noncytopathic
BVDV may produce persistently infected (PI) offspring
that serve as a reservoir for viral spread as a consequence
of lifelong shedding of BVDV from all mucosal sur-
faces.3,4 Under experimental conditions, noncytopathic
BVDV persistence may occur in 86–100% of calf fetuses
infected in the susceptible gestational period.5
The incidence or risk of immune tolerance to BVDV
and subsequent persistent viremia as a consequence of
early fetal infection has not been previously explored in
alpacas under conditions of natural virus exposure. In
2003, Wentz et al6 failed to achieve PI in the offspring of
4 pregnant llamas experimentally inoculated with 3
llama-derived BVDV isolates (type 1a and 1b) during
early gestation. BVDV type Ib isolates, however, recently
were sequenced and identified in 35 crias classified as PI
after natural infection in North America.7 A BVDV sero-
prevalence study (May 2006 to July 2007) of 63 registered
alpaca breeders, representing 26 US states, furthermore
identified a 6.3% prevalence of PI crias at the time of in-
vestigation.1 These findings underscore the importance
of identification and elimination of PI in susceptible
herds.
In cattle, BVDV has been associated with pathology in
several organs, including the respiratory, hematologic,
immunologic, neurologic, and reproductive systems.
Acute infection of an immunocompetent animal most
commonly leads to subclinical infection, although clini-
cal signs of lethargy, fever, anorexia, decreased milk
production, lymphopenia, thrombocytopenia, diarrhea,
and death because of fulminating disease also may occur
in some cases.8,9 To date, only individual case reports
have documented the clinical manifestation of BVDV in-
fections in SACs. In llamas, BVDV infection has been
associated with respiratory disease, abortion, ill thrift,
and diarrhea.10,11 Goyal et al12 first isolated a non-
cytopathic BVDV type Ib of alpaca origin from a
stillborn cria. Subsequently, the 1st PI alpaca cria was
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identified after evaluation of multiple abortions in eastern
Ontario.13 Postmortem evaluation further demonstrated
a diagnosis of BVDV type Ib in 3 British alpacas with ill
thrift and diarrhea.11,14 Another PI case was identified
after diagnostic evaluation of a premature cria with
chronic respiratory disease, anemia, and failure to thrive.15
Based on these individual reports, the clinical manifesta-
tions of BVDV in camelids appear diverse.
The insidious nature of BVDV may lead to substantial
economic losses in the camelid industry if chronic or per-
sistent virus carriers are not identified in the herd. The
purpose of this study was to classify and differentiate the
long-term clinicopathological characteristics of tran-
siently infected and PI alpaca crias, after natural BVDV
type Ib exposure. We hypothesized that PI alpacas may
be differentiated from healthy controls and transiently
BVDV-infected alpacas based on growth retardation,




Thirty-five alpaca crias and 1 fetus naturally exposed to BVDV
type Ib at 5 different northeastern US alpaca farms were evaluated
between September 2005 and September 2008. Animals were in-
cluded in the study based on positive whole blood polymerase chain
reaction (PCR) test results, virus isolation, BVDV type I serum
neutralizing antibody (SN) analysis, and DNA sequencing at the
Animal Health Diagnostic Center at Cornell University.
A diagnosis of persistent BVDV infection was based on a mini-
mum of 2 consecutive positive whole blood PCR results at43-week
intervals and subsequent immunohistochemistry (IHC) confirma-
tion at necropsy of all animals that died. Live PI animals at the time
of study completion were required to demonstrate persistent vi-
remia in the absence of endogenous serum neutralizing antibodies to
BVDV. Chronic infection was differentiated from acute infection
based on extended viremia (43 weeks) followed by an increasing
BVDV type I neutralizing antibody titer. Virus isolation confirmed
positive whole blood PCR results. In total, data were collected from
14 persistently BVDV-infected crias, 1 aborted fetus, 18 animals
acutely exposed to BVDV, 3 chronically infected (Fig 1), and 19
control animals consisting of non-BVDV-infected crias from the
same cohort.
Chronically infected and PI crias were removed from their orig-
inating farms and raised in group isolation over a period of 2 years.
In contrast, all acutely infected and control animals were raised in
their home environment. Management and environmental condi-
tions for control and BVDV-infected animals were similar,
including access to fresh grass, free choice hay, and 0.5 kg concen-
tratea per adult animal per day, as directed by the owner. All
animals44 months of age were dewormed with Doramectinb every
6 weeks.
Data Collection
Signalment, history, clinical signs, sequential PCR and SN, com-
plete necropsy, and IHC were obtained whenever possible, and
outcome was documented based on survival, euthanasia, or death.
Clinical examinations of acutely infected animals were limited to
owner observation. In contrast, the behavior, clinical examination
abnormalities, feed intake, nursing activity, and fecal output were
monitored daily by a licensed veterinarian for chronically infected
and PI animals. Body weight was recorded at monthly intervals.
CBC analyses were performed at the time of study enrollment and
biannually thereafter, as dictated by the duration of the crias’ sur-
vival. Hematological results obtained at sequential time points were
averaged for each animal in order to limit bias because of age and
repeated analysis of long-term survivors. A single CBC dataset per
animal therefore was compared between age-matched BVDV in-
fected (mean age, 7.9 months) and cohort control animals (mean
age, 7.6 months). A CBC also was obtained within 3–6 weeks after
resolution of viremia in chronically infected animals.
At postmortem examination, tissue samples were collected for
histopathology, fixed in 10% neutral buffered formalin, routinely
processed and embedded in paraffin according to standard histo-
logic technique. Five-micron-thick sections were prepared and
stained routinely with hematoxylin and eosin for microscopic ex-
amination. Sections also were stained for immunohistochemical
detection of BVDV antigen by use of an avidin-biotin alkaline
phosphatase method.16
Virus Isolation
All virus isolations were performed using primary bovine testic-
ular cell cultures in T-25 flasks. Eagle’s Minimal Essential Mediumc
was supplemented with 10% g-irradiated fetal bovine serum free of
antibodies to type 1 and type 2 BVDV. Samples for inoculation
consisted of serum or mononuclear cells. Mononuclear cells were
added to cell monolayers without freezing. After overnight incuba-
tion, the monolayers were rinsed with medium and MEM 1 10%
FBS was added. After 5–7 days, monolayers were trypsinized and a
sample of the cells was tested for the presence of BVDV using a
BVDV monoclonal antibody 20.10.6 in an indirect fluorescent anti-
body test. Negative cultures were retested after an additional 5–7
days of incubation.7
Serum Virus Neutralization (SN) Test
Serum was harvested from blood samples collected by direct
venipuncture. Neutralizing antibody titers were determined by
combining serial dilutions (1 : 4–1 : 512) of heat-inactivated (561C
for 30 minutes) serum with BVDV type 1 (Singer strain) or BVDV
type 2 (strain 125; 100–300 TCID50/50mL) in 96-well microtiter
plates for 1 hour at 371C with 5% CO2. After incubation, 20,000–
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Fig 1. Origin of persistently and chronically bovine viral diarrhea
virus-infected alpaca crias. Cria I, PI ( farm I—born 2005); Cria II,
chronically infected ( farm I—born 2005); Cria III, chronically in-
fected ( farm II—born 2006); Cria IV, PI ( farm III—born 2006);
Cria V–VII, PI ( farm V—born 2006); Cria VIII–XIV, PI ( farm I—
born 2006); Cria XV, chronically infected ( farm I—born 2006).
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25,000 bovine testicular cells were added to each well and incubated
5 days at 371C with 5% CO2. Cells were examined microscopically
for changes associated with viral cytopathic effects (CPE), and titers
of virus-neutralizing antibodies were recorded as the reciprocal
of the highest serum dilution that inhibited CPE, as described
previously.17
Real-Time RT-PCR
A real-time RT-PCR assay (RRT-PCR) with a commercial real-
time PCR unitd was utilized as described previously.7 50 UTRRRT-
PCR was performed with a commercial real-time PCR reagent kit.e
The RRT-PCR mixture consisted of 12.5mL of 2 Master Mix,
0.625mL of 40 MultiScribe and RNase Inhibitor Mix, 0.3mM of
each primer, 5mL of template RNA, 0.1 mM of BVDV probe, and
water up to 25mL. Thermocycling was performed at 481C for 30
minutes to synthesize the first-strand cDNA, 951C for 10 minutes to
inactivate reverse transcriptase, 40 cycles of 951C for 15 seconds,
and 601C for 1 minute. A standard curve was constructed in each
experiment using serial dilutions of the cell culture supernatant of
the Singer strain of BVDV with a titer of 3  106 50% tissue culture
infectious dose per milliliter (TCID50/mL). The relative number of
BVDV genome copies in the clinical samples was measured by com-
paring their threshold cycle (CT) values to those of the standards. A
threshold value usually is set when the fluorescence reaches 10 times
the standard deviation of the baseline signal.
Statistical Methods
All historical, clinical, laboratory, and necropsy data were re-
ported descriptively. Statistical differences between animal groups
were evaluated via the independent samples t-test by commercial
software,f with an accepted significance level of P o .05. All data
were presented asmean standard deviation (SD) ormedian inter-
quartile range based on the normality of data distribution
(Kolmogorov-Smirnov test). The duration of BVDV infection and
presence of serum neutralizing antibody responses were docu-
mented from the time of BVDV diagnosis to the time of death or
completion of the study in September 2008 in surviving alpacas.
Results
Alpaca Farm I
A BVD PI alpaca cria (cria I) was born on farm I in
September 2005. Its dam was exposed to BVDV type Ib
before entering farm I at 168 days gestation, based on
retroactive BVDV testing of the originating farm where
2 PI crias were identified. PI of cria I was confirmed by
3 consecutive positive whole blood PCRs between 6 and
20 weeks of age, virus isolation, and subsequent IHC at
necropsy (4.7 months of age). At the time of parturition,
the cria’s dam was whole blood PCR negative and SN
antibody positive (titer of 64). Farm I had no history of
previous BVDV exposure and 72% of alpacas in direct
contact (5 acre pasture) with cria I, seroconverted over
the next 9 weeks (36/58 animals; 62%) or 14 weeks (6/58;
10%), respectively.
A total of 11 pregnant females in the 1st trimester of
pregnancy were naturally exposed to BVDV over a
period of 50 days (range, 11–87 days) based on
seroconversion. The mean gestation of pregnant dams
at the beginning of BVDV exposure was 64 days (95%
CI: 47–82 days; range, 11–102 days). The virus was ex-
pected to circulate for a minimum of 2 weeks after
removal of the PI and 1 chronically infected cria from
the premises, extending average virus exposure until day
114 of pregnancy (95% CI: 100–130 days; range, 74–152
days). One exposed pregnant female was intentionally
aborted at 146 days of gestation. BVDV infection of the
aborted fetus was subsequently confirmed by IHC at
necropsy. The remaining 10 exposed pregnant females
were removed from the premises in the last trimester of
pregnancy and allowed to deliver their crias at a private
isolation facility (see ‘‘cohort study’’ below).
In addition, 19 juvenile, nonweaned alpacas were first
exposed to BVDV at a mean age of 76 days (95% CI: 56–
96 days; range, 1–121 days) on farm I, based on serocon-
version and PCR analysis. Of these, 6 alpaca crias were
viremic at the time of 1st PCR analysis and cleared the
virus from their blood stream within 3 weeks of identifi-
cation. Eighty-nine percent (17/19) of transiently BVDV
exposed crias remained clinically healthy based on owner
observation. Morbidity and mortality was limited to 2
viremic crias that were born 1 day before and 14 days af-
ter the birth of the PI cria in the same pasture. One
neonate died peracutely, showing histologic evidence of
pleural and subpleural hemorrhage, multifocal mucosal
petechiae of the esophagus and urinary bladder, mild he-
patocellular necrosis, diffuse vascular congestion, as well
as villus and crypt epithelial cell necrosis within the small
intestine. The second cria (cria II) was admitted to the
Tufts Cummings School of Veterinary Medicine at 11
days of age, for an acute onset of yellow, watery diarrhea,
and weakness progressing to collapse. Presenting clinical
abnormalities included fever, tachycardia, weakness and
recumbency, moderate lethargy, diarrhea, a grade II/VI
systolic heart murmur, hyperemic mucous membranes,
and hypovolemia. Cria II remained hospitalized for 21
days with a diagnosis of enterocolitis, confirmed sepsis
and prolonged BVDV infection. Extended viremia was
identified, based on 3 sequential whole blood PCRs at 12,
20, and 57 days of age, followed by confirmatory virus
isolation.
Alpaca Farm II
Farm II identified 1 congenitally infected alpaca cria
(cria III) with extended viremia, based on routine herd
screening. Three whole blood PCR tests between 1 and
67 days of age confirmed prolonged viremia, in conjunc-
tion with increasing BVDV type 1 antibody titers.
Alpaca Farms III–V
Farm III detected 1 PI alpaca cria (cria IV) on routine
herd screening, after the day of parturition. Farm IV sim-
ilarly identified 2 PI alpacas (1 male, 1 female) at 7 and 19
months of age based on 2 consecutively positive whole
blood PCRs, and confirmed the diagnosis by IHC at sub-
sequent necropsy. In addition, Farm V detected 3 PI
alpaca crias (crias V–VII) after parturition, obtaining
sequentially positive whole blood PCR results, virus
isolation and subsequent IHC confirmation at necropsy
(5, 6, and 7.5 months of age).
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Cohort Evaluation
Ten pregnant female alpacas from farm I with con-
firmed BVDV type Ib exposure during the 1st trimester
of pregnancy (64–114 days of gestation) were removed
from their originating premises and clinically studied
throughout their last 60 days of gestation (summer
2006) at a private isolation facility. Clinical signs of ill-
ness were not observed throughout the adult animals’
stay and 9 of 10 females delivered unassisted (stage 2
labor o 15 minutes). One alpaca, with a history of
previous dystocia, had a breech delivery of a BVDV neg-
ative full-term dead fetus. In total, transplacental fetal
infection was confirmed in 9/11(82%) pregnant female
alpacas naturally exposed to BVDV during early gesta-
tion at farm I. This resulted in the birth of 7 PI alpaca
crias (7/10 [70%] deliveries; 1 animal was aborted), 2
noninfected neonates (including the stillborn dystocia),
as well as 1 congenitally infected cria (cria XV) with ex-
tended viremia. Prolonged viremia was identified, based
on 6 consecutive BVDVwhole blood PCRs at 4–251 days
of age, confirmed by virus isolation.
Prospective Assessment of PI and Chronically
Infected Crias
The above-described 8 intrauterine BVDV infected,
live-born crias from farm I (7 PI, 1 chronically infected;
VIII–XV) were raised in group isolation and prospec-
tively evaluated over the next 2 years (2006–2008).
Similarly, crias I–VII were transferred from their home
farms and raised at an isolated facility, after confirma-
tion of extended viremia (43 weeks). In total, 12 live PI
crias (7 female, 5 male) were enrolled for prospective
assessment. Data collection also included clinicopatho-
logical information obtained retrospectively from 2 PI
crias (1 male, 1 female) raised on farm IV.
PI crias were differentiated from 3 chronically infected
crias (II, III, and XV; 2 female, 1 male) with prolonged
viremia for 457 days, 467 days, and 4251 days, re-
spectively. A single positive SN titer of 4,096 was
obtained for cria II at 129 days postpartum. Cria III
was negative for serum neutralizing antibodies at 40 days
postpartum and subsequently had titers of 32 (days 166
and 213), 768 (day 456), and 384 (day 529). Cria XV
demonstrated sequential SN titers of 124 (day 0, post-
colostrum), 64 (day 59), 48 (day 203), 96 (day 250), 384
(day 493), and 192 (day 566). All chronically infected
crias were removed from PI exposure at 135 days (cria
II), 486 days (cria III), and 523 days postpartum (cria
XV), respectively, leading to a documented reduction in
SN titers in the latter 2 animals.
Two noninfected females and 1 male cria born in iso-
lation to 3 of the 11 BVDV-exposed pregnant dams from
farm I (see ‘‘cohort evaluation’’ above) served as control
animals. In the 2 years preceding and following PI births
(2006), 16 healthy crias (10 female, 6 male) were born to
the same 11 dams from farm I and were available as ad-
ditional controls (half-siblings; years of parturition:
2004–2005 and 2007–2008).
Chronically infected (n 5 3; P 5 .031) and PI crias
(n 5 11; Po .001) for which data were available showed
significantly lower mean birth weights (6.6 0.82 and 6.4
 1.0 kg, respectively) compared with noninfected, co-
hort control animals (n 5 16; 8  0.95 kg). A relative
reduction in growth rates similarly was evident between
control and PI crias over a 2-year observational period,
during which body weights were significantly higher in
controls at all time points (Fig 2). In contrast, gestational
age was comparable between animal groups (PI: 332 
14 days, n 5 11; chronically infected crias: 330  5.7
days, n 5 3; cohort controls: 334  9 days, n 5 19).
PI alpacas had significant anemia (P 5 .001) as well as
relative (P 5 .024) and absolute blood monocytosis (P 5




























n=16 n=11 n=8 n= 9 n=7 n=7 n=6 n=6 n=5 n=5 n=12 n=5 n=8 n=3
Fig 2. Growth curves of persistently bovine viral diarrhea virus-infected crias compared with healthy controls. BVDV PI, alpacas persis-
tently infected with bovine viral diarrhea virus type 1b.
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iron concentrations were determined in 4 PI (mean, 47.7
 18.5mg/dL; reference range for llamas, 70–148mg/
dL)18 and 2 chronically infected alpacas (mean, 120 
17.4mg/dL) at 2 separate time points, indicating low se-
rum iron concentrations in all tested PI animals. CBC
were indistinguishable between PI and chronically in-
fected, viremic crias (P 4 .05). After virus clearance,
however, recovered alpacas demonstrated a significant
increase (normalization) in total WBC count (P 5 .02)
and absolute lymphocyte counts (P 5 .025), as well as a
relative reduction in monocytes (P 5 .013) compared
with results obtained during viremia.
Thirteen of 14 PI alpacas (93%) suffered from various
clinical illnesses during their lifetime, most commonly
chronic wasting (9/14), diarrhea (7/14; recurrent in 4 ani-
mals), and respiratory tract disease (7/14, chronic
intermittent signs in 3/7), which was associated with puru-
lent, bilateral nasal discharge in 6 of 7 affected animals. In
addition, transient cutaneous papillomas were present in 3
neonatal alpacas originating from the same farm. Periocu-
lar andmucocutaneous hyperkeratosis surrounding the lips
(1), a congenital mature cataract (1), neonatal encepha-
lopathy (1), septic arthritis (1), and suri-type fleece (1) were
observed in 1 animal each. Unilateral corneal ulcers devel-
oped in 2 alpacas and were recurrent in 1 animal. As of
December 2010, 2 PI alpacas have remained free of clinical
signs for a period of 52 and 54 months, respectively, aside
from 1 episode of transient diarrhea in 1 animal and evi-
dence of cutaneous hyperkeratosis in both animals.
A diagnosis of partial or complete failure of passive
transfer (FPT) was based on immunoglobulin G concen-
trations o800mg/dL and was documented in 6/11 PI
(55%), 2/3 chronically infected, and 0/13 cohort control
animals for which data were available. Commercial
plasmag (30mL/kg) was administered to all animals with
FPT. Of the 2 PI alpacas that remained clinically healthy
long term, only 1 experienced FPT postpartum. Post-
colostral serum neutralizing BVDV antibodies were
detected in 4 of 9 PI crias for which data were available.
One of these PI crias maintained a low seropositive
BVDV titer (1 : 8) until the last sampling date before its
death, at 123 days postpartum.
Overall, 50% of PI crias died acutely within 6 months
after parturition (7/14), with a median age of 177 days
(interquartile range, 555 days) at the time of death for all
PI animals. The mortality rate reached 64% (9/14) and
79% (11/14) by 1 and 2 years, respectively. In contrast,
all chronically infected alpacas and controls were alive at
the end of the 2-year observation period. Detailed histo-
pathological data, including analysis of viral distribution
in PI crias that died are reported elsewhere (Henningson
JN, Steffen DJ, Topliff CL et al. Systemic distribution of
viral antigen in alpacas persistently infected with bovine
pestivirus. Vet Path, under review).
Discussion
The current study allowed for a unique long-term, pro-
spective characterization of transient (acute or chronic) and
persistent BVDV infection in domestic alpacas because of
natural noncytopathic BVDV type Ib exposure. Acute in-
fection remained subclinical inmost study alpacas, based on
owner assessment. However, similar to our observations in
2 neonatal crias, transient infection may result in clinical
signs of diarrhea, lethargy, oculonasal discharge, anorexia,
and pyrexia in some animals.2 Ecchymotic hemorrhages
with hepatocellular and epithelial crypt cell necrosis of the
small intestine were observed after the peracute death of 1
transiently infected alpaca cria. Systemic hemorrhage was
most likely related to endotoxemia and suspected dissemi-
nated intravascular coagulation. Peracute BVDV infections
also have been reported in cattle and may result in severe
diseasemanifestation and higher fatality rates. In both cattle
and calves, a thrombocytopenic, hemorrhagic syndrome has
been associated with bloody diarrhea, ecchymoses, epistax-
is, and petechiae. This syndrome has been experimentally
linked to BVDV type 2 infection in cattle,19 but has not been
reported in camelids to date.
The current study is the 1st documentation of pro-
longed BVDV viremia in alpacas, which extended for
more than 57, 67, and 251 days in 3 alpacas, respectively,
after perinatal (n 5 1) as well as intrauterine (congenital)
BVDV infection (n 5 2). The virus can be recovered from
blood and nasal secretions of acutely infected cattle for
6–8 days, although higher virulence isolates may result in
a longer duration of viral shedding.16,20 PI animals are un-
able to produce serum neutralizing antibodies against the
infecting noncytopathic BVDV strain because of the










n 10 3 3 16
WBC (103/mL) 8.1 (2.5)a 7.3 (2.1)a 12.0 (0.8)b 10.8 (4.4)a,b
Hct (%) 23.4 (3.7)a 26.1 (2.6)a/b 29.0 (5.7)a/b 28.9 (3.3)b
Neutrophils (%) 60.1 (18)a 56.3 (6.7)a 49.0 (8.3)a 52.7 (13.4)a
Lymphocytes (%) 31.9 (16.6)a 35.7 (5.8)a 45.0 (10.3)a 41.8 (16.2)a
Monocytes (%) 5.7 (3.6)a/c 6.7 (1.5)a 2.7 (0.6)b/c 2.1 (1.6)b
Neutrophils (103/mL) 5.1 (3.1)a 4.0 (1.8)a 6.1 (0.8)a 5.5 (2.3)a
Lymphocytes (103/mL) 2.4 (1.3)a 2.3 (1.0)a 5.2 (1.1)b 4.6 (3.4)a/b
Monocytes (103/mL) 0.41 (0.26)a 0.42 (0.18)a 0.3 (0.1)a/b 0.21 (0.14)b
Chronic infection, crias with extended BVD viremia 43 weeks; n, number of animals for which data were available (results of sequential
analyses in individual animals were averaged before data entry); WBC, white blood cell count.
Changes in superscript letters within rows indicate significant differences between groups (P o .05).
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presence of immune tolerance. PI therefore is routinely de-
termined by the isolation of BVDV from peripheral blood
leukocytes or serum on 2 separate occasions at least 3
weeks apart,21 in the absence of endogenous, homologous
neutralizing antibodies. However, PI animals can respond
immunologically to heterologous strains of BVDV, so that
a seropositive status cannot be utilized diagnostically to
rule out PI.22 Because ingestion of colostrum also may lead
to measurable BVDV serum antibodies, a definitive differ-
entiation between persistent and chronic infection in crias
may only be possible once maternal antibodies have dissi-
pated. Calves with maternal antibodies to BVDV type 1
and 2 are estimated to become seronegative by 141 days
and 114 days postpartum, respectively.23 In the current
study, 1 PI alpaca cria still had a low (titer of 8) maternal
BVDV antibody titer at 123 days after parturition. Serum
antibody titers also remained low for the first 6 months of
life in transiently infected crias with extended viremia, sug-
gesting a delayed acquired immunity to BVDV and
response to exogenous BVDV exposure because of co-
housing with PI alpacas. One of the affected animals (cria
III) became PCR negative before development of substan-
tial serum neutralizing antibodies, which may suggest that
both colostral and cell-mediated immunity play a role in
BVDV elimination in the postnatal period. Protective im-
mune responses against BVDV that may not be reflected
by serum antibody titers can be mounted in calves by pas-
sive immunity.24
Transplacental infection was identified in 9/11 (82%)
naı̈ve, pregnant alpacas naturally exposed to BVDV type
Ib during early gestation, with confirmed viral persistence
in 7/10 live-born crias. Similarly, BVDV persistence has
been reported in 86–100% of calf fetuses infected before
reaching immunocompetence.25 PI infection is the result of
in utero, noncytopathic BVDV infection during the fetal
development period between 45 and 125 days of gestation
in cattle. This gestational period encompasses the time
from the end of the embryonic stage to the development of
fetal immunocompetence,2 which has not been determined
in camelids to date. The mean gestation of alpacas at the
beginning and end of virus exposure was 64 and 114 days,
respectively, in the current study. In comparison, a previ-
ous report documented the birth of a PI cria after BVDV
type 1b exposure at 65 days of gestation.13 Experimental
infection with llama-derived BVDV isolates (type 1a and
1b) in 4 pregnant llamas between days 65 and 105 of ges-
tation did not result in fetal infection or birth of PI crias in
a previous study.6 In contrast, PI crias were born to preg-
nant alpacas after intranasal inoculation with BVDV type
1b strains of alpaca or cattle origin in a recent report,
whereas BVDV type 2 exposure did not produce persistent
fetal infection despite ability to induce seroconversion.26,27
These data support that unique BVDV type 1b genotypes
are able to establish transplacental infection in alpacas
after both natural and experimental viral exposure.2
Transplacental infection therefore may maintain unique
bovine BVDV 1b genotypes within the alpaca population
whereas de novo introductions of BVDV genotypes appear
to be low, based on previous reports.7
PI alpaca crias experience a high degree of morbidity
and mortality, associated with several different clinical
disease manifestations. These findings may relate to an
impaired immune response in PI animals, facilitating op-
portunistic infection and early death. Reported clinical
abnormalities of PI alpacas include stillbirth, low-grade
pyrexia, atypical fleece, lethargy, unthriftiness, in-
appetence, low birth weight, poor weight gain, diarrhea,
joint swelling, as well as signs of opportunistic dental, in-
testinal, upper or lower respiratory disease, based on
individual case reports.10,11,13–15 Similar observations
were obtained from the current study, where low birth
weights, chronic wasting, diarrhea, and respiratory tract
disease were most prevalent in PI alpacas. Transiently
infected alpacas with extended viremia also demon-
strated low birth weights. Stunted growth was observed
in 1 of 3 chronically infected animals, which also experi-
enced prolonged postpartum morbidity because of
enterocolitis and confirmed sepsis. These data support
that the peripartum phenotypic characteristics of PI crias
may be clinically indistinguishable from those of chron-
ically infected crias with extended viremia.
There are several limitations of the current study,
which included a heterogenous animal population from
different farms. Certain observations, including postpar-
tum behavioral analyses and monitoring, therefore were
performed by the owners and may have limited our abil-
ity to identify subtle clinical changes in these animals.
Management practices were similar for all animals, al-
though some differences in environment and handling
may have impacted our comparison between study ani-
mals and controls. The impact of genetic factors was
minimized by choosing age-matched animals of similar
genetic background (same dam) as control animals.
BVDV has been shown to replicate in bovine lympho-
cytes and macrophages, inducing lymphocyte depletion
and sometimes neutropenia.28 A recent study comparing
BVDV PI and healthy heifers under field conditions iden-
tified a leukopenia and neutropenia, with relative
lymphocytosis in PI versus control heifers. Blood mono-
cytes were significantly decreased both in number and in
proportion when compared with control heifers, suggest-
ing that these cells are one of the major virus targets in
cattle.28 Acute, experimental challenge of postpartum
calves with BVDV type 2 similarly induced a significant
drop in all circulating leukocytes (neutrophils, lympho-
cytes, and monocytes) by days 3 or 5 postexposure.29 In
contrast to cattle, PI and chronically infected, viremic al-
pacas displayed both relative and absolute monocytosis
compared with controls, which was likely a response to
opportunistic infection. Additionally, significant anemia
(Table 1) was observed in alpacas with persistent viremia.
Low hemoglobin concentration and hematocrit similarly
were documented in a PI alpaca and BVDV-infected
llama of 2 previous reports.10,15
Hematologic parameters were indistinguishable be-
tween PI and chronically infected, viremic alpacas and
may not aid in clinical differentiation between these pa-
tient groups. Nonetheless, chronically infected alpacas
showed a significant increase (normalization) in both to-
tal WBC and absolute lymphocytes after resolution of
viremia. However, total WBC, lymphocyte, and neutro-
phil counts were not statistically different between PI
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alpacas and healthy controls. Previously, a report of a
BVDV-infected llama identified leukocytosis, despite ev-
idence of lymphoid depletion and thymic atrophy.10 Our
results suggest that persistent BVDV infection of alpacas
under field conditions may have a minor or variable im-
pact on lymphocytes and neutrophils, in comparison
with results obtained after experimental, acute infec-
tion29 or natural PI28 in cattle.
Inadequate transfer of passive immunity (FPT) was prev-
alent in both PI (6/11, 55%) and chronically BVD-infected
crias (2/3, 66%) and was most likely related to less vigorous
or delayed nursing activity in viremic crias. In contrast,
healthy half siblings (n 5 16) born within the 2 years pre-
ceding and after a PI birth by the same dam showed
adequate transfer of maternal immunoglobulins. Inade-
quate passive immunity therefore may contribute to
opportunistic infection in PI alpacas within the first weeks
of life. Opportunistic infection and impaired immune re-
sponses may contribute to early death in PI alpacas, because
BVDV also is known to infect cells that are instrumental in
the control of both the innate and acquired immune system.
The highest mortality (7/14, 50%) was observed within
the first 6 month of life in PI crias of the current study.
However, some PI alpacas were born without clinical ab-
normalities and were impossible to distinguish
phenotypically form healthy cohorts, similar to observa-
tions in cattle.2 Although stunted growth was common in
PI crias, 2 animals of the current report grew normally and
showed minimal morbidity long term. This observation
further underscores the importance of routine BVDV-spe-
cific diagnostic testing (eg, PCR, serum neutralizing
antibody testing, virus isolation) in order to identify PI
and chronically infected camelids, which serve as a major
source of viral spread within and among farms.
Footnotes
a Evans Alpaca Maintenance, Blue Seal Feeds, Londonderry, NH
bDectomax, Pfizer Animal Health, Exton, PA
c Invitrogen/GIBCO, Grand Island, NY
dAB 7,900, Applied BioSystems, Carlsbad, CA
eTaqman EZ RT-PCR kit, Applied BioSystems
f SPSS, version 12, SPSS Inc, Chicago, IL
gTriple J Farms, Kent Labs, Bellingham, WA
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Supporting Information
Additional Supporting Information may be found in
the online version of this article:
Figure S1. Phenotypic appearance of persistently
BVDV infected alpacas. (a) Normally developed 4 month
old BVDV PI Huacaya alpaca cria with ‘‘suri-like’’ fleece.
(b) Markedly stunted 2 month old BVDV PI Huacaya
alpaca cria. (c) Normally developed 10 month old BVDV
PI Huacaya alpaca. (d) Mildly stunted 10 month old
BVDV PI Huacaya alpaca. (e) Large-sized 3 12 year old
BVDV PI Huacaya alpaca [matured alpaca (c)]. (f)
Stunted 3 12 year old BVDV PI Huacaya alpaca with
chronic dermatitis (white facial discoloration) [matured al-
paca (d)].
Please note: Wiley-Blackwell is not responsible for the
content or functionality of any supporting materials sup-
plied by the authors. Any queries (other than missing
material) should be directed to the corresponding author
for the article.
Disclaimer: Supporting information is published as
submitted and not corrected or checked for scientific
content, typographical errors, or functionality. The re-
sponsibility for scientific accuracy remains entirely with
the authors.
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